Search results with tag "Transmucosal"
Medication Treatment Guidelines for Substance Use ...
www.hca.wa.govJan 26, 2021 · Medication Treatment Guidelines for Substance Use Disorders (SUDs) - Transmucosal Buprenorphine Medical policy no. 65.20.00.10-3 Effective: November 1, 2019 Related medical policies: • Sublocade (65.20.00.E5)
The Transmucosal Immediate Release Fentanyl (TIRF) REMS ...
www.tirfremsaccess.com1 1I haI vheriI awdeIrhwtITdhRFE1havMeServAchsuvwAvhAvvh1Tuuho vAS eternhFriI awdeIrcherSuTMernhPgm,lhbfEpFpK.k I understand that TIRF medicines are only available ...
The Transmucosal Immediate Release Fentanyl …
www.tirfremsaccess.com3 1PresPrceib PrsNaiPbeNmP*ae(pl1escnitibc):eIucN)ce)cce1*uuedrc)trimibhepb PrsNaiPb:eibtu*nibheTRFoyefglkpkwv, Prescriber Name* (please print): patient privacy Notice for the TIRf ReMS access program — For the purpose of the TIRF REMS Access
Frequently Asked Questions (FAQs)
www.tirfremsaccess.com2 I. ALL STAKEHOLDERS FAQs What is a TIRF medicine? TIRF medicines are transmucosal immediate release fentanyl prescription medicines used to manage breakthrough pain in adults with cancer who are routinely taking other opioid (narcotic)
Prescribing Information | SUBLOCADE™ (buprenorphine ...
www.sublocade.com4 . 26 . 2.3 Recommended Dosing 27 The recommended dose of SUBLOCADE following induction and dose adjustment with transmucosal 28 buprenorphine is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg
TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) …
www.fda.govInitial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Transmucosal Immediate Release Fentanyl (TIRF) Products ...
www.tirfremsaccess.comTransmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists